Table 2 Estimation of patients with severe uncontrolled asthma in Italy, by dupilumab eligibility [29]

-

All patients

100.0%

n/a

n/a

n/a

n/a

19,960

1

EOS ≥ 150 cells/μL and FeNO ≥ 25 ppb and IgE ≥ 30 IU/mL

24.8%

✔

✔

✓

Yes

4950

2

EOS ≥ 150 cells/μL and FeNO < 25 ppb and IgE ≥ 30 IU/mL

16.7%

✔

✓

Yes

3333

3

EOS < 150 cells/μL and FeNO ≥ 25 ppb and IgE ≥ 30 IU/mL

5.7%

✔

✓

Yes

1138

4

EOS ≥ 150 cells/μL and FeNO ≥ 25 ppb and IgE < 30 IU/mL

16.8%

✔

✔

Yes

3353

5

EOS ≥ 150 cells/μL and FeNO < 25 ppb and IgE < 30 IU/mL

13.2%

✔

Yes

2635

6

EOS < 150 cells/μL and FeNO ≥ 25 ppb and IgE < 30 IU/mL

2.9%

✔

Yes

579

7

EOS < 150 cells/μL and FeNO < 25 ppb and IgE ≥ 30 IU/mL

(10.5%)

✓

No

(2096)

8

EOS < 150 cells/μL and FeNO < 25 ppb and IgE < 30 IU/mL

(9.4%)

No

(1876)

-

All dupilumab-eligible patients

80.1%

n/a

n/a

n/a

Yes

15,988